Ashley Gallagher, MA

Many states are pushing pharmacies to move beyond the traditional dispensing role into more robust clinical care.

Combined with nutritional interventions, semaglutide also demonstrates greater weight loss compared with dulaglutide.

From proposed transparency rules to Medicare price negotiation programs, the stakes are high for pharmacy reimbursement and the sustainability of independent practices.

The FDA clears secukinumab for patients 12 years and older with tough hidradenitis suppurativa, offering weight-based IL‑17A biologic relief and new guidance on screening and safety.

Remote hub model in New Zealand upskills pharmacists to launch automated insulin delivery faster, expanding equitable access for type 1 diabetes.

This landmark decision follows previous approvals for adults 60 years and older, as well as those aged 50 to 59 years at increased risk.

Eli Lilly flags unknown impurities in compounded tirzepatide with B12 as FDA targets misleading GLP-1 marketing.

FDA approves Wellcovorin for rare FOLR1 cerebral folate deficiency, spotlighting real-world evidence, dosing goals, and key drug-interaction risks.

A study finds prior-authorization bans do not boost buprenorphine retention for patients on private insurance.

Mark Cuban Cost Plus Drug Company challenges pharmacy benefit managers' opacity, expands affordable drug access, and supports community pharmacies.

Clinical pharmacists boost A1c control and eye and foot screening for Spanish-speaking adults with diabetes, revealing why culturally fluent care matters.

Pharmacists’ word choices shape insulin-pump trust, reduce diabetes stigma, and uncover hidden needs—boosting adherence and A1C outcomes.

Previously, bimagrumab monotherapy in adults with type 2 diabetes led to a 20.5% reduction in total body fat mass and a 0.76 percentage point decrease in hemoglobin A1c.

Harps pharmacists reveal how smart workflow powers point‑of‑care testing, prescribing, and billing—scalable clinical services for regional chains.

The FDA approves Sotyktu, the first selective TYK2 oral pill for active psoriatic arthritis, improving joints and skin with key safety monitoring.

GLP-1 diabetes drugs show promise in cutting addiction risk and overdose deaths, hinting at new options for substance use disorder prevention and care.

Once weekly petrelintide, a long-acting amylin analog, delivers up to 10.7% weight loss with placebo-like gastrointestinal tolerability in phase 2.

In older adults with type 2 diabetes, low body mass index signals higher mortality risk.

Precision nutrition reshapes type 2 diabetes prevention, using genes, epigenetics, and microbiome insights to tailor diets that improve glycemic control.

Weekday sleep near 7 hours optimizes insulin sensitivity, and too little or too much could harm metabolism.

Phase 3 data show subcutaneous risankizumab boosts remission and endoscopic healing in moderate-to-severe Crohn cases, with familiar safety and easier dosing.

FDA targets telehealth ads for compounded glucagon-like peptide-1s, warning of misleading claims, hidden sources, and safety risks amid social media hype.

FDA expands lomitapide use to children 2 years and older, highlighting major low-density lipoprotein reductions.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

A large study links an early A1c under 6.5% to fewer eye and nerve complications, urging pharmacists to intensify control and monitor retinopathy.

The FDA expands the drug's usage to treat idiopathic short stature, small for gestational age, and growth failure associated with Noonan syndrome.

Pharmacists can close the gap between recommendations and uptake for pregnant women.

Phase 3 trials show once-daily bictegravir/lenacapavir keeps HIV suppressed after switching regimens, with strong safety and better satisfaction for complex-treatment patients.

Orforglipron beats oral semaglutide in A1C and weight loss in a head-to-head study for type 2 diabetes.